THE NETHERLANDS – January 1, 2016 – Synaffix BV, a biotechnology company exclusively focused on the development of industry-leading antibody-drug conjugate (ADC) technology platforms, today announced that it will present its latest data from a preclinical model of lymphoma at the upcoming Biotech Showcase on January 12 in San Francisco.
Presentation Details
Date Jan 12, 2016
Time 3:00pm PT
Location Parc 55 Hilton
Copyright Synaffix BV 2021. All Rights Reserved
Bring your own and/or choose from the following categories.
Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.
Early preclinical data available on request.
NK cell recruitment
NK cell recruitment
Forming an integral part of every toxSYN®
linker-payload, HydraSpace® bears a negative charge at physiological pH and improves:
GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).
| toxSYN® Linker-Payload |
Mode-of-Action | Payload (Active Catabolite) |
|---|---|---|
| 1. SYNtecan E™* | Topoisomerase 1 inhibitor | Camptothecin-based |
| 2. SYNeamicin D™* | DNA damaging agent |
Calicheamicin-based |
| 3. SYNeamicin G™* | ||
| 4. SYN-PNU™* | Nemorubicin-based | |
| 5. SYNstatin E™ | Microtubule inhibitors |
Auristatin-based |
| 6. SYNstatin F™ | ||
| 7. SYNtansine™ | Maytansine-based |
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace®
** N-6-aminohexanoyl-maytansine (Ahx-maytansine)
